Pediatric Central Line Skin Reactions Lack Rx Protocols

You May Be Interested In:Former reality TV star appointed NASA Interim Administrator


TOPLINE:

A survey of dermatologists found that although all respondents receive inpatient central line dressing (CLD)-related consults, most lack standardized protocols for managing adverse skin reactions and reported varying management approaches.

METHODOLOGY:

  • Researchers developed and administered a 14-item Qualtrics survey to 107 dermatologists providing pediatric inpatient care through the Society for Pediatric Dermatology’s Inpatient Dermatology Section and Section Chief email lists.
  • A total of 35 dermatologists (33%) from multiple institutions responded to the survey; most respondents (94%) specialized in pediatric dermatology.
  • Researchers assessed management of CLD-associated adverse skin reactions.

TAKEAWAY:

  • All respondents reported receiving CLD-related consults, but 66% indicated there was no personal or institutional standardized approach for managing CLD-associated skin reactions.
  • Respondents said most reactions were in children aged 1-12 years (19 or 76% of 25 respondents) compared with those aged
  • Management strategies included switching to alternative products, applying topical corticosteroids, and performing patch testing for allergies. 

IN PRACTICE:

“Insights derived from this study, including variation in clinician familiarity with reaction patterns, underscore the necessity of a standardized protocol for classifying and managing cutaneous CLD reactions in pediatric patients,” the authors wrote. “Further investigation is needed to better characterize CLD-associated allergic CD [contact dermatitis], irritant CD, and skin infections, as well as at-risk populations, to better inform clinical approaches,” they added.

SOURCE:

The study was led by Carly Mulinda, Columbia University College of Physicians and Surgeons, New York, and was published online on December 16 in Pediatric Dermatology.

LIMITATIONS:

The authors noted variable respondent awareness of institutional CLD and potential recency bias as key limitations of the study.

DISCLOSURES:

Study funding source was not declared.The authors reported no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

share Paylaş facebook pinterest whatsapp x print

Similar Content

At Oval Office, Elon Musk Defends Controversial DOGE Work
At Oval Office, Elon Musk Defends Controversial DOGE Work
A Los Angeles Teen Started a Recovery Fund for Fire Victims
A Los Angeles Teen Started a Recovery Fund for Fire Victims
Risk Score Predicts GI Bleeding Among Post-PCI Patients
Risk Score Predicts GI Bleeding Among Post-PCI Patients
Myanmar Earthquake Death Toll Rises to Over 3,000
Myanmar Earthquake Death Toll Rises to Over 3,000
FDA APPROVED vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) over a computer rendering of cystic fibrosis.
Next-in-Class Once-Daily Pill Approved for Cystic Fibrosis
FDA Approves First and Only Therapy for IgG4-RD
FDA Approves First and Only Therapy for IgG4-RD
Today's Insight | © 2024 | News